Moral dilemma(s) in human papillomavirus vaccination – revisiting the role of the herd effect

References

1. Colzani E, Johansen K, Johnson H, Pastore Celentano L. Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma. Euro Surveill. 2021;26(50):2001659.  https://doi.org/10.2807/1560-7917.ES.2021.26.50.2001659 
2. Ortu G, Barret A-S, Danis K, Duchesne L, Levy-Bruhl D, Velter A. Low vaccination coverage for human papillomavirus disease among young men who have sex with men, France, 2019. Euro Surveill. 2021;26(50):2001965.  https://doi.org/10.2807/1560-7917.ES.2021.26.50.2001965 
3. Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP. Mumps and rubella eliminated from Finland. JAMA. 2000;284(20):2643-7.  https://doi.org/10.1001/jama.284.20.2643  PMID: 11086376 
4. World Health Organization Regional Office for Europe (WHO/Europe). Measles and rubella elimination: verification process continues amid COVID-19 pandemic. Copenhagen: WHO/Europe; 13 Aug 2020. Available from: https://www.euro.who.int/en/countries/sweden/news/news/2020/8/measles-and-rubella-elimination-verification-process-continues-amid-covid-19-pandemic
5. Vänskä S, Luostarinen T, Baussano I, Apter D, Erikson T, Natunen K, et al. Vaccination with moderate coverage eradicates oncogenic HPV if a gender-neutral strategy is applied. J Infect Dis. 2020;222:948-56.  https://doi.org/10.1093/infdis/jiaa099  PMID: 32161969 
6. Gray P, Kann H, Pimenoff VN, Eriksson T, Luostarinen T, Vänskä S, et al. HPV seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A Cross-sectional cohort analysis following a cluster-randomised trial. PLoS Med. 2021;18:e1003588.  https://doi.org/10.1371/journal.pmed.1003588  PMID: 34097688 
7. Malmqvist E, Helgesson G, Lehtinen J, Natunen K, Lehtinen M. The ethics of implementing HPV vaccination. Med Health Care Philos. 2011;14:19-27.  https://doi.org/10.1007/s11019-010-9285-9  PMID: 20853152 
8. Mariz FC, Gray P, Bender E, Eriksson T, Kann H, Apter D, et al. Sustainability of bi- and quadrivalent HPV vaccine-induced neutralizing antibodies. Lancet Infect Dis. 2021;10:1458-68.  https://doi.org/10.1016/S1473-3099(20)30873-2  PMID: 34081923 
9. Kann H, Lehtinen M, Eriksson T, Surcel H-M, Dillner J, Faust H. Sustained cross-reactive antibody responses after human papillomavirus vaccinations. Up to 12 years follow-up in the Finnish Maternity Cohort. J Infect Dis. 2021;223(11):1992-2000.  https://doi.org/10.1093/infdis/jiaa617  PMID: 33009576 
10. Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340-8.  https://doi.org/10.1056/NEJMoa1917338  PMID: 32997908 
11. Gargano JW, You M, Potter R, Alverson G, Swanson R, Saraiya M, et al. An evaluation of dose-related HPV vaccine effectiveness using central registries in Michigan. Cancer Epidemiol Biomarkers Prev. 2021;cebp.0625.2021. PMID: 34663615